Qin Yuan, Ma Fu-Yuan, Zhang Zhi, Zhao Chen-Hao, Huang Biao
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China.
World J Gastrointest Oncol. 2024 Nov 15;16(11):4514-4517. doi: 10.4251/wjgo.v16.i11.4514.
In this article, an article published in the , which focuses on whether the expression of programmed death-ligand 1 (PD-L1) affects the effectiveness of chemotherapy regimens, including bevacizumab, in treating patients with colorectal cancer (CRC). Through neutralization of vascular endothelial growth factor (VEGF), bevacizumab inhibits tumor angiogenesis, impairing neovascularization and thereby depriving the tumor of essential nutrients and oxygen. Conversely, PD-L1 binding to VEGF receptor 2 promotes angiogenesis, supporting tumor vasculature. The interplay between these pathways complicates the assessment of bevacizumab's efficacy in cancer therapy, notably in CRC, where VEGF and PD-L1 significantly affect treatment response. This review examines metastatic CRC treatment strategies, focusing on bevacizumab's mechanism of action and the role of PD-L1 in this therapeutic context.
在本文中，一篇发表在[期刊名称未给出]上的文章聚焦于程序性死亡配体1（PD-L1）的表达是否会影响包括贝伐单抗在内的化疗方案治疗结直肠癌（CRC）患者的疗效。通过中和血管内皮生长因子（VEGF），贝伐单抗抑制肿瘤血管生成，破坏新血管形成，从而剥夺肿瘤必需的营养物质和氧气。相反，PD-L1与VEGF受体2结合会促进血管生成，支持肿瘤脉管系统。这些通路之间的相互作用使得评估贝伐单抗在癌症治疗中的疗效变得复杂，尤其是在CRC中，VEGF和PD-L1会显著影响治疗反应。本综述探讨转移性CRC的治疗策略，重点关注贝伐单抗的作用机制以及PD-L1在这种治疗背景下的作用。
